drugset
drugset / Trial / NCT04215003

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

NCT04215003 ↗

Phase 1/2 Unknown 20 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design, umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with breast cancer.

Timeline

Start
2020-01-20
Primary completion
2024-12-01
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 600 mg Intravenous
Subject Carboplatin Small molecule 2 unknown Intravenous
Subject Dalpiciclib Small molecule 125 mg —
Subject Goserelin Other / unclassified 3.6 mg Intramuscular
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Pertuzumab Monoclonal antibody 420 mg Intravenous
Subject Trastuzumab Monoclonal antibody 4 mg/kg Intravenous

Indications

breast cancer